Related references
Note: Only part of the references are listed.Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun
Pantelis Sarafidis et al.
JOURNAL OF HYPERTENSION (2021)
Magnetic Resonance Kidney Parenchyma-T2 as a Novel Imaging Biomarker for Autosomal Dominant Polycystic Kidney Disease
Florian Siedek et al.
INVESTIGATIVE RADIOLOGY (2020)
Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease
Tajdida A. Magayr et al.
KIDNEY INTERNATIONAL (2020)
Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling
Caroline R. Sussman et al.
CELLULAR SIGNALLING (2020)
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD
Sravanthi Lavu et al.
JCI INSIGHT (2020)
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
Ronald D. Perrone et al.
KIDNEY INTERNATIONAL REPORTS (2020)
No Change in Nocturia After NOCTURNE
Esther Meijer et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease
Bart J. Kramers et al.
KIDNEY INTERNATIONAL (2020)
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
Manuel A. Anderegg et al.
KIDNEY MEDICINE (2020)
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
Ron T. Gansevoort et al.
KIDNEY INTERNATIONAL (2019)
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease
Alan S. L. Yu et al.
KIDNEY INTERNATIONAL (2019)
Autosomal dominant polycystic kidney disease
Emilie Cornec-Le Gall et al.
LANCET (2019)
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial
Franz Schaefer et al.
EUROPEAN JOURNAL OF PEDIATRICS (2019)
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease
Salim S. Hayek et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation
Beili Shi et al.
SCIENTIFIC REPORTS (2019)
Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
Bart J. Kramers et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease
Roslyn J. Simms et al.
EUROPEAN RADIOLOGY (2019)
Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure
Mayumi Endo et al.
KIDNEY INTERNATIONAL REPORTS (2019)
Comparison of Different Selection Strategies for Tolvaptan Eligibility among Autosomal Dominant Polycystic Kidney Disease Patients
Vera C. Wulfmeyer et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Intrafamilial Variability of ADPKD
Matthew B. Lanktree et al.
KIDNEY INTERNATIONAL REPORTS (2019)
Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors
A. Lianne Messchendorp et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Emilie Cornec-Le Gall et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials
Godela M. Brosnahan et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD
Matei Neagu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan
Tsuyoshi Yamaguchi et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Marie E. Edwards et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Tolvaptan slows disease progression in late-stage ADPKD
Albert C. M. Ong
NATURE REVIEWS NEPHROLOGY (2018)
Case report: a thiazide diuretic to treat polyuria induced by tolvaptan
Bart J. Kramers et al.
BMC NEPHROLOGY (2018)
Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease
A. Lianne Messchendorp et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Fouad T. Chebib et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease
Marcelo F. Cassini et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression
Monica Furlano et al.
AMERICAN JOURNAL OF NEPHROLOGY (2018)
Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
Roman-Ulrich Mueller et al.
CLINICAL KIDNEY JOURNAL (2018)
Management of autosomal-dominant polycystic kidney disease-state-of-the-art
Roman-Ulrich Mueller et al.
CLINICAL KIDNEY JOURNAL (2018)
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial
Olivier Devuyst et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
Susan E. Shoaf et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease
Vicente E. Torres et al.
KIDNEY INTERNATIONAL (2017)
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease
Timothy L. Kline et al.
KIDNEY INTERNATIONAL (2017)
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial (vol 32, 2017)
Vicente E. Torres et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3: 4
Olivier Devuyst et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Polycystic Kidney Disease and the Vasopressin Pathway
Maatje D. A. van Gastel et al.
ANNALS OF NUTRITION AND METABOLISM (2017)
Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease
Chengli Shen et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
Niek F. Casteleijn et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease
Emilie Cornec-Le Gall et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease
Christina M. Heyer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease
Mandi Salih et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
The importance of total kidney volume in evaluating progression of polycystic kidney disease
Jared J. Grantham et al.
NATURE REVIEWS NEPHROLOGY (2016)
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Ron T. Gansevoort et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function
Wendy E. Boertien et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Paul B. Watkins et al.
DRUG SAFETY (2015)
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease
Harpreet Bhutani et al.
KIDNEY INTERNATIONAL (2015)
Autosomal dominant polycystic kidney disease: the changing face of clinical management
Albert C. M. Ong et al.
LANCET (2015)
Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials
Maria V. Irazabal et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease
York Pei et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Dysnatremias in Patients With Kidney Disease
Sara Combs et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
Vicente E. Torres et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Predictors of Autosomal Dominant Polycystic Kidney Disease Progression
Robert W. Schrier et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry
Edwin M. Spithoven et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation
Thien Anh Ho et al.
KIDNEY INTERNATIONAL (2012)
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Water Prescription in Autosomal Dominant Polycystic Kidney Disease: A Pilot Study
Connie J. Wang et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
A Pilot Clinical Study to Evaluate Changes in Urine Osmolality and Urine cAMP in Response to Acute and Chronic Water Loading in Autosomal Dominant Polycystic Kidney Disease
Irina Barash et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
